All News Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-02 pm EDT			5-day change	1st Jan Change
937.6 ^USD	+3.78%		+5.27%	+6.75%

May. 02	Morgan Stanley Raises Price Target on Regeneron Pharmaceuticals to $1,183 From $1,177	MT
May. 02	Piper Sandler Adjusts Regeneron Pharmaceuticals' Price Target to $1,000.25 From $1,016	MT

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Morgan Stanley Raises Price Target on Regeneron Pharmaceuticals to $1,183 From $1,177	May. 02	MT
Piper Sandler Adjusts Regeneron Pharmaceuticals' Price Target to $1,000.25 From $1,016	May. 02	MT
RBC Cuts Price Target on Regeneron Pharmaceuticals to $1,185 From $1,189	May. 02	MT
Global markets live: Etsy, Qualcomm, Carvana, Rio Tinto, Apple...	May. 02
Sector Update: Health Care Stocks Mixed Premarket Thursday	May. 02	MT
Regeneron Pharmaceuticals : May 2024 Corporate Presentation	May. 02	PU
Transcript : Regeneron Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 02, 2024	May. 02
Regeneron: Adjusted EPS down 4% in Q1	May. 02	CF
Fed, Earnings Outlooks Lift Wall Street Pre-Bell; Asia Mixed, Europe Off	May. 02	MT
Regeneron Pharmaceuticals 1Q Revenue Declines Amid Lower EYLEA Sales	May. 02	DJ
Regeneron Pharmaceuticals' Q1 Non-GAAP Net Income, Revenue Decline	May. 02	MT
Stock Futures Gain Pre-Bell as Fed Leaves Key Rate Unchanged; Asia, Europe Churn	May. 02	MT
Earnings Flash (REGN) REGENERON PHARMACEUTICALS Reports Q1 Revenue $3.15B, vs. Street Est of $3.22B	May. 02	MT
Regeneron: Q1 Earnings Snapshot	May. 02	AQ
Earnings Flash (REGN) REGENERON PHARMACEUTICALS Reports Q1 EPS $9.55, vs. Street Est of $10.10	May. 02	MT
Regeneron misses profit estimates on weaker Eylea and Dupixent sales	May. 02	RE
Regeneron Reports First Quarter 2024 Financial and Operating Results	May. 02	GL
Regeneron Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases	Apr. 29	GL
Regeneron Faces Q1 Seasonality Despite Eylea HD Launch, Oppenheimer Says	Apr. 26	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

All News

Filters